Definium Therapeutics, Inc.
NMS: DFTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Definium Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get DFTX Z-Score →About Definium Therapeutics, Inc.
Healthcare
Biotechnology
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
📊 Fundamental Analysis
Definium Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -64.1%, which indicates that capital utilization is currently under pressure.
At a current price of $21.53, DFTX currently trades near the top of its 52-week range (96%) (Range: $5.36 - $22.12).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$2.15B
Trailing P/E
--
Forward P/E
-12.60
Beta (5Y)
2.56
52W High
$22.12
52W Low
$5.36
Avg Volume
1.72M
Day High
Day Low